Orfiril (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril, is an anticonvulsant presented as a tablet for oral use. It is used to treat seizure disorders and is prescribed for patients requiring long‑term seizure control.

GNH USA supplies Orfiril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Orfiril is an antiepileptic drug that is employed across several seizure‑related conditions: - Epilepsy: helps control generalized tonic‑clonic and absence seizures. - Bipolar disorder: stabilises mood and reduces the frequency of manic episodes. - Migraine prophylaxis: decreases the number of migraine attacks when other therapies are insufficient.

Adverse reactions to sodium valproate can vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild gastrointestinal upset. - Tremor: fine shaking of the hands. - Weight gain: gradual increase in body weight. - Hair loss: diffuse thinning of scalp hair. - Drowsiness: increased sleepiness during the day. - Elevated liver enzymes: mild, often transient changes in liver function tests.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury that may be life‑threatening. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain. - Thrombocytopenia: low platelet count increasing bleeding risk. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hyperammonemia: elevated blood ammonia levels causing confusion. - Fetal teratogenicity: risk of birth defects when used in pregnancy.

When prescribing sodium valproate, clinicians should consider several safety aspects: - Liver function monitoring: check baseline enzymes and repeat periodically. - Blood count surveillance: monitor platelets and white blood cells regularly. - Pregnancy risk: avoid use in women of childbearing potential unless no alternative exists. - Drug interactions: review concomitant medications for potential PK/PD effects. - Renal function: assess kidney health in patients with impairment. - Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Sodium valproate interacts with a range of medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce valproate levels and increase seizure risk. - Phenobarbital: can lower valproate concentrations, diminishing seizure control. - Topiramate: combined use raises risk of metabolic acidosis.

Moderate Interactions (Monitor Closely): - Warfarin: valproate may enhance anticoagulant effect, requiring INR monitoring. - Lamotrigine: increased risk of skin reactions, especially rash. - Oral contraceptives: valproate can decrease hormonal efficacy, risking unintended pregnancy.